Checkpoint Therapeutics, Inc.
CKPT · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $17 | $6 | $4 |
| Gross Profit | $0 | -$17 | -$6 | -$4 |
| % Margin | – | – | – | -10,826.8% |
| R&D Expenses | $4 | $17 | $6 | $4 |
| G&A Expenses | $7 | $12 | $3 | $2 |
| SG&A Expenses | $7 | $12 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $29 | $10 | $7 |
| Operating Income | -$11 | -$29 | -$10 | -$7 |
| % Margin | – | – | – | -16,275.6% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$11 | -$29 | -$10 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$29 | -$10 | -$7 |
| % Margin | – | – | – | -16,268.3% |
| EPS | -18.74 | -0.7 | -0.23 | -0.18 |
| % Growth | -2,577.1% | -204.3% | -27.8% | – |
| EPS Diluted | -18.74 | -0.7 | -0.23 | -0.18 |
| Weighted Avg Shares Out | 1 | 40 | 43 | 37 |
| Weighted Avg Shares Out Dil | 1 | 40 | 43 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$11 | -$29 | -$10 | -$7 |
| % Margin | – | – | – | -16,275.6% |